X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMM-6-415 is a Deep Cyclic Inhibitor (DCI) of the MAPK pathway designed with unique drug-like properties. It is being evaluated for the treatment of advanced solid tumors with RAF or RAS mutations.
Lead Product(s): IMM-6-415
Therapeutic Area: Oncology Product Name: IMM-6-415
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of MEK of the MAPK pathway with once-daily oral dosing.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with RAS-mutant pancreatic ductal adenocarcinoma.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
IMM-1-104 is an oral, once-daily deep cyclic inhibitor, small molecule drug. It is being evaluated for the treatment of patients with pancreatic ductal adenocarcinoma.
Lead Product(s): IMM-1-104,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
IMM-6-415 is a deep cyclic inhibitor (DCI) of the MAPK pathway designed with unique drug-like properties. It is being evaluated for the treatment of advanced solid tumors with RAF or RAS mutations.
Lead Product(s): IMM-6-415
Therapeutic Area: Oncology Product Name: IMM-6-415
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.
Lead Product(s): IMM-1-104
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
Immuneering intends to use the net proceeds to advance the preclinical and clinical development of its product candidates, including IMM-1-104, a novel, allosteric dual-MEK inhibitor designed for better applicability to RAS mutant tumors by preventing MEK reactivation.
Lead Product(s): IMM-1-104
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2023
Details:
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily dosing. It is being evaluated for advanced solid tumors harboring RAS mutations.
Lead Product(s): IMM-1-104
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
IMM-1-104 aims to achieve pan-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through deep cyclic inhibition of the MAPK pathway with once-daily dosing.
Lead Product(s): IMM-1-104
Therapeutic Area: Oncology Product Name: IMM-1-104
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
IMM-6-415 is a third generation dual MEK inhibitor with a differentiated deep cyclic inhibition mechanism that aims to dynamically modulate MAPK pathway signaling. IMM-6-415 was designed with unique drug-like properties that distinguish it from other programs of Immuneering.
Lead Product(s): IMM-6-415
Therapeutic Area: Oncology Product Name: IMM-6-415
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
